- Home
- Research
- Mental Health
- Differences in substance use among trans, non-binary and cis people in Spain: a cross-sectional study.
Cannabis use highest among all groups, disparities reflect structural vulnerabilities
Differences in substance use among trans, non-binary and cis people in Spain: a cross-sectional study.
AI Summary
This Spanish cross-sectional study examined substance use patterns among 19,948 individuals (including 1,582 transgender and non-binary people) to compare drug consumption between TNBP and cisgender populations. Cannabis emerged as the most frequently used substance across all demographic groups in both past-12-month and past-month assessments. The research found that transgender women and non-binary individuals showed significantly higher prevalence ratios for nearly all substances compared to their cisgender peers, while transgender men demonstrated elevated use for most substances.
The study revealed important disparities in substance use patterns, with adjusted prevalence ratios (aPRs) being highest for poppers, while cannabis and cocaine showed smaller gaps between TNBP and cis populations. This suggests that while cannabis use is elevated across TNBP communities, the substance use disparities are more pronounced for certain drugs. The researchers emphasized that these differences likely reflect structural vulnerabilities and cultural-social specificities within transgender and non-binary communities rather than inherent risk factors.
The findings have significant implications for public health policy and cannabis regulation, indicating that harm reduction and substance use interventions must be tailored to address the specific needs and circumstances of TNBP populations. Understanding these disparities is crucial for developing culturally competent healthcare approaches and addressing underlying social determinants that may drive higher substance use in these communities.
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Review describes AHC and reports cannabidiol as an additional treatment option
Review finds school prevention often covers cannabis, but evidence gaps remain
Antipsychotics eased symptoms, but relapse-prevention evidence remains thin
Explore More Research
Stay informed about the latest cannabis science.